Healthcare

CT:VQ moved from regulatory clearance into commercial deployment during FY2026. The technology received US Food and Drug Administration clearance in September 2025, while the US Centers forMedicare& Medicaid Services subsequently confirmed reimbursement of US$650.50 per scan. According to 4DMedical, CT:VQ enables ventilation-perfusion assessment from …

For the twelve months to 30 June 2026, Ramsay reported underlying net profit after tax after non-controlling interests of $364.1 million, up 19.3% on the prior year, or 22.9% on a constant-currency basis. Australian underlying EBIT rose 11.2% to $639.8 million, supported by higher …

Best Practice Software has integrated Lyrebird Scribe into Bp Premier, allowing clinicians to generate structured clinical notes, letters and other documentation from consultations within the practice-management system. This is relevant because it shows that Sonic’s broader healthcare ecosystem is extending beyond diagnostics alone and …

The company recorded substantial non-cash impairments during FY26, with a significant portion associated with CSL Vifor. The specialty medicinesBusinesshas faced generic competition and product-related pressures. CSL also incurred restructuring costs as it progressed organisational changes and cost-reduction measures.

Under the terms of the agreement, the US$1.65 billion upfront consideration will be structured as follows: US$1.25 billion will be paid to ITM sellers in the form of 105.8 million Telix shares, priced at the 30-day trailingVWAPas of signing of US$11.84 per share, released …

The centrepiece of 4DMedical's FY26 result was the commercialisation of CT:VQ, the world's first and only non-contrast, CT-based ventilation-perfusion imaging technology. The product received FDA clearance in September 2025, with the US Centers for Medicare & Medicaid Services confirming reimbursement of US$650.50 per scan …

Artrya's FY26 results detailed the transition of its Salix platform — which analyses cardiac CT angiography (CCTA) scans to deliver real-time insights on heart health, high-risk plaque and coronary flow — from development into commercial deployment. The company secured three commercial US customers during …